Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Financings
Financings
| Raise | Date |
|---|---|
| Private placement of common stock Announced: about US$5.6M · US$1.16 a share · Alexander Capital, L.P. Dealers: Alexander Capital, L.P. (lead) Buyers: John Paul DeJoria (additional $1.0 million investment) Use of proceeds: Clinical development of Telomir-Zn, including its Phase 1/2 program in advanced or metastatic TNBC, plus working capital and general corporate purposes | Oct 6, 2026 |
| Capital contributions from former TELI shareholders Closed: US$1M raised Buyers: Certain former TELI shareholders ($1.0 million funded at closing; up to an additional $4.0 million in milestone-based contributions) | Apr 27, 2026 |
| Milestone shares of common stock Announced: up to US$5M Buyers: certain TELI shareholders (up to $5 million in cash or cash equivalents: $1 million at closing, $2 million upon IND acceptance, $2 million upon Phase 1/2 initiation) Use of proceeds: To advance development of Telomir-1 | Oct 21, 2025 |
| Strategic investment of restricted shares of common stock Closed: US$3M raised · US$3 a share Buyers: The Bayshore Trust (1 million restricted shares at $3.00 per share for $3 million) Insiders: Purchased entirely by The Bayshore Trust, the Company's largest shareholder Use of proceeds: Fund Telomir-1's upcoming IND submission for a rare disease indication and strengthen the balance sheet | May 21, 2025 |
| Strategic investment of common stock Closed: US$1M in the latest tranche · US$7 a share Buyers: The Starwood Trust ($1 million in common stock at $7 per share) Use of proceeds: To advance its scientific research and product development activities | Dec 17, 2024 |